Increasing Transparency in Generic Drug Applications Act of 2022
This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-03-10 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2022-03-09 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2022-03-09 | IntroReferral | Introduced in House | Library of Congress |